Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes

Jung Wan Choe, Hyo Jung Kim, Jae Seon Kim, Jaehyung Cha, Moon Kyung Joo, Beomjae Lee, Jong Jae Park, Young-Tae Bak

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Generally, carbohydrate antigen 19–9 (CA 19–9) is not useful for screening pancreatic cancer in the asymptomatic general population. This study aimed to evaluate the utility of CA 19–9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes. Methods: We retrospectively reviewed the medical records of patients who visited our health promotion center for health check-ups without cancer related symptoms from January 2005 to January 2014, and were newly diagnosed with diabetes mellitus (DM) within 2 years before their visit. Results: Of the 5111 asymptomatic patients with new-onset DM (<2 years) selected for analyses, 87 (1.7%) eventually developed pancreatic cancer after the health check-up. In the subgroup of 322 patients with high total bilirubin levels (>1.7 mg/dL) at the screening time, 42 (73.7%) of 57 patients with high CA 19–9 levels (>37 IU/mL) had been diagnosed as pancreatic cancer during follow-up period and 12 (4.5%) of 265 patients with normal CA 19–9 levels had finally developed pancreatic cancer (OR = 16.3). In the subgroup of 4789 patients with normal bilirubin levels, pancreatic cancer had been detected in 20 (3.8%) of 522 patients with high CA 19–9 level, while only 13 (0.3%) in 4267 patients with normal CA 19.9 levels (OR = 12.6), respectively. Conclusion: CA 19–9 levels after a diagnosis of new-onset DM could be a useful biomarker of pancreatic cancer, especially in patients with high serum bilirubin.

Original languageEnglish
JournalHepatobiliary and Pancreatic Diseases International
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Pancreatic Neoplasms
Early Detection of Cancer
Carbohydrates
Antigens
Diabetes Mellitus
Health Promotion
Bilirubin
Medical Records
Biomarkers
Serum
Population

Keywords

  • Bilirubin
  • Carbohydrate antigen 19–9
  • Diabetes mellitus
  • Early detection of cancer
  • Pancreatic neoplasms

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

@article{7a6f9026a025499fb4c1a540e9dd06b8,
title = "Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes",
abstract = "Background: Generally, carbohydrate antigen 19–9 (CA 19–9) is not useful for screening pancreatic cancer in the asymptomatic general population. This study aimed to evaluate the utility of CA 19–9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes. Methods: We retrospectively reviewed the medical records of patients who visited our health promotion center for health check-ups without cancer related symptoms from January 2005 to January 2014, and were newly diagnosed with diabetes mellitus (DM) within 2 years before their visit. Results: Of the 5111 asymptomatic patients with new-onset DM (<2 years) selected for analyses, 87 (1.7{\%}) eventually developed pancreatic cancer after the health check-up. In the subgroup of 322 patients with high total bilirubin levels (>1.7 mg/dL) at the screening time, 42 (73.7{\%}) of 57 patients with high CA 19–9 levels (>37 IU/mL) had been diagnosed as pancreatic cancer during follow-up period and 12 (4.5{\%}) of 265 patients with normal CA 19–9 levels had finally developed pancreatic cancer (OR = 16.3). In the subgroup of 4789 patients with normal bilirubin levels, pancreatic cancer had been detected in 20 (3.8{\%}) of 522 patients with high CA 19–9 level, while only 13 (0.3{\%}) in 4267 patients with normal CA 19.9 levels (OR = 12.6), respectively. Conclusion: CA 19–9 levels after a diagnosis of new-onset DM could be a useful biomarker of pancreatic cancer, especially in patients with high serum bilirubin.",
keywords = "Bilirubin, Carbohydrate antigen 19–9, Diabetes mellitus, Early detection of cancer, Pancreatic neoplasms",
author = "Choe, {Jung Wan} and Kim, {Hyo Jung} and Kim, {Jae Seon} and Jaehyung Cha and Joo, {Moon Kyung} and Beomjae Lee and Park, {Jong Jae} and Young-Tae Bak",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.hbpd.2018.04.001",
language = "English",
journal = "Hepatobiliary and Pancreatic Diseases International",
issn = "1499-3872",
publisher = "HBPD INT Press",

}

TY - JOUR

T1 - Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes

AU - Choe, Jung Wan

AU - Kim, Hyo Jung

AU - Kim, Jae Seon

AU - Cha, Jaehyung

AU - Joo, Moon Kyung

AU - Lee, Beomjae

AU - Park, Jong Jae

AU - Bak, Young-Tae

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Generally, carbohydrate antigen 19–9 (CA 19–9) is not useful for screening pancreatic cancer in the asymptomatic general population. This study aimed to evaluate the utility of CA 19–9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes. Methods: We retrospectively reviewed the medical records of patients who visited our health promotion center for health check-ups without cancer related symptoms from January 2005 to January 2014, and were newly diagnosed with diabetes mellitus (DM) within 2 years before their visit. Results: Of the 5111 asymptomatic patients with new-onset DM (<2 years) selected for analyses, 87 (1.7%) eventually developed pancreatic cancer after the health check-up. In the subgroup of 322 patients with high total bilirubin levels (>1.7 mg/dL) at the screening time, 42 (73.7%) of 57 patients with high CA 19–9 levels (>37 IU/mL) had been diagnosed as pancreatic cancer during follow-up period and 12 (4.5%) of 265 patients with normal CA 19–9 levels had finally developed pancreatic cancer (OR = 16.3). In the subgroup of 4789 patients with normal bilirubin levels, pancreatic cancer had been detected in 20 (3.8%) of 522 patients with high CA 19–9 level, while only 13 (0.3%) in 4267 patients with normal CA 19.9 levels (OR = 12.6), respectively. Conclusion: CA 19–9 levels after a diagnosis of new-onset DM could be a useful biomarker of pancreatic cancer, especially in patients with high serum bilirubin.

AB - Background: Generally, carbohydrate antigen 19–9 (CA 19–9) is not useful for screening pancreatic cancer in the asymptomatic general population. This study aimed to evaluate the utility of CA 19–9 level as a screening indicator of pancreatic cancer in asymptomatic patients with new-onset diabetes. Methods: We retrospectively reviewed the medical records of patients who visited our health promotion center for health check-ups without cancer related symptoms from January 2005 to January 2014, and were newly diagnosed with diabetes mellitus (DM) within 2 years before their visit. Results: Of the 5111 asymptomatic patients with new-onset DM (<2 years) selected for analyses, 87 (1.7%) eventually developed pancreatic cancer after the health check-up. In the subgroup of 322 patients with high total bilirubin levels (>1.7 mg/dL) at the screening time, 42 (73.7%) of 57 patients with high CA 19–9 levels (>37 IU/mL) had been diagnosed as pancreatic cancer during follow-up period and 12 (4.5%) of 265 patients with normal CA 19–9 levels had finally developed pancreatic cancer (OR = 16.3). In the subgroup of 4789 patients with normal bilirubin levels, pancreatic cancer had been detected in 20 (3.8%) of 522 patients with high CA 19–9 level, while only 13 (0.3%) in 4267 patients with normal CA 19.9 levels (OR = 12.6), respectively. Conclusion: CA 19–9 levels after a diagnosis of new-onset DM could be a useful biomarker of pancreatic cancer, especially in patients with high serum bilirubin.

KW - Bilirubin

KW - Carbohydrate antigen 19–9

KW - Diabetes mellitus

KW - Early detection of cancer

KW - Pancreatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85046670107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046670107&partnerID=8YFLogxK

U2 - 10.1016/j.hbpd.2018.04.001

DO - 10.1016/j.hbpd.2018.04.001

M3 - Article

C2 - 29752133

AN - SCOPUS:85046670107

JO - Hepatobiliary and Pancreatic Diseases International

JF - Hepatobiliary and Pancreatic Diseases International

SN - 1499-3872

ER -